Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D2E4CG
|
|||
Drug Name |
Amiselimod
|
|||
Synonyms |
Amiselimod; 942399-20-4; Amiselimod [INN]; Amiselimod free base; Amiselimod(MT-1303) free base; 942399-20-4 (free base); 358M5150LY; 2-amino-2-(4-(heptyloxy)-3-(trifluoromethyl)phenethyl)propane-1,3-diol; 2-Amino-2-(2-(4-heptyloxy-3-trifluoromethylphenyl)ethyl)propane-1,3-diol; 2-amino-2-[2-[4-heptoxy-3-(trifluoromethyl)phenyl]ethyl]propane-1,3-diol; 2-Amino-2-{2-[4-(heptyloxy)-3-(trifluoromethyl)phenyl]ethyl}propane-1,3-diol; UNII-358M5150LY; Amiselimod,MT1303; Amiselimod (USAN/INN); AMISELIMOD [USAN]; AMISELIMOD [WHO-DD]; MT-1303 FREE BASE; GTPL9319; SCHEMBL2463680; CHEMBL3707375; JVCPIJKPAKAIIP-UHFFFAOYSA-N; DTXSID301141402; BCP24738; EX-A1427; MT1303; AKOS032971355; Example 1 [US20090137530]; D10905; MT-1303; MT1303; MT 1303; Q27256444; 1,3-PROPANEDIOL, 2-AMINO-2-(2-(4-(HEPTYLOXY)-3-(TRIFLUOROMETHYL)PHENYL)ETHYL)-; 2-Amino-2-[2-[4-(heptyloxy)-3-(trifluoromethyl)phenyl]ethyl]-1,3-propanediol
Click to Show/Hide
|
|||
Drug Type |
Small molecule
|
|||
Indication | Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 2 | [1] | |
Company |
Salix Pharmaceuticals Bridgewater, NJ
|
|||
Structure |
Download2D MOL |
|||
Formula |
C19H30F3NO3
|
|||
Canonical SMILES |
CCCCCCCOC1=C(C=C(C=C1)CCC(CO)(CO)N)C(F)(F)F
|
|||
InChI |
InChI=1S/C19H30F3NO3/c1-2-3-4-5-6-11-26-17-8-7-15(12-16(17)19(20,21)22)9-10-18(23,13-24)14-25/h7-8,12,24-25H,2-6,9-11,13-14,23H2,1H3
|
|||
InChIKey |
JVCPIJKPAKAIIP-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Sphingosine-1-phosphate receptor 2 (S1PR2) | Target Info | Modulator | [2] |
KEGG Pathway | Sphingolipid signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Pathway Interaction Database | S1P3 pathway | |||
Sphingosine 1-phosphate (S1P) pathway | ||||
S1P2 pathway | ||||
Reactome | G alpha (i) signalling events | |||
Lysosphingolipid and LPA receptors | ||||
WikiPathways | Signal Transduction of S1P Receptor | |||
Small Ligand GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04857112) A Phase 2, Randomized, Double-Blinded, Placebo Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects With Mild to Moderate Ulcerative Colitis (UC). U.S.National Institutes of Health. | |||
REF 2 | Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol. 2017 Jan;174(1):15-27. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.